Compare Fubotv Inc (FUBO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Mesoblast Limited — how do they compare? Fubotv Inc trades at $9.02 (market cap $1.02B), while Mesoblast Limited trades at $14.32 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Mesoblast Limited for 14 Days on average.
| FUBO | MESO | |
|---|---|---|
Market Cap | $1.02B | $1.75B |
Volume | 978,631 | 239,027 |
Sector | Media | Health |
52-Week High | $48.96 | $20.96 |
52-Week Low | $8.09 | $13.19 |
Typical Hold Time | 35 Days | 14 Days |
Enterprise Value | $1.19B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.03, down 2.38% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M in 2025, representing a significant turnaround from previous losses. Recent developments include new sports streaming agreements with NHL teams and expanded partnerships with The Athletic, positioning the company for continued subscriber growth.
FUBO presents a compelling turnaround story with deep valuation discounts (P/E 2.43, P/S 0.19) and analyst consensus target of $63.38 suggesting 600%+ upside. However, risks include persistent cash flow challenges, high debt levels, and intense streaming competition. The Disney partnership and sports content expansion provide catalysts, but execution risk remains elevated given the company's history of losses.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
